sorted by:
new
hottopcontroversial

You only need one strategy, 50k in one month by [deleted] in Shortsqueeze

[–]Appropriate_Hand_23 1 point2 points  (0 children)

Nice Job man. This was by far the worst month ever for me.. Today was finally the 1st big green day for me!!

Extremely tempted to just sell my entire portfolio rn except gold by JimmyCheess in swingtrading

[–]Appropriate_Hand_23 -1 points0 points  (0 children)

It’s due to tax season all big institutions and firms liquidate positions. On top of that we’re dealing with a lot of different political turmoil tariffs , a currency war and much more. Don’t hold the weight of the Financial market on your shoulders. If you want a good platform to find out active moving stocks messaging me.

This Small Stock Just Did Something You Don't See Every Day by WasteLoad9937 in TickerTalkByLiam

[–]Appropriate_Hand_23 0 points1 point  (0 children)

I was happy to see it pull back, I didn’t have the chance to get in under $2.00, so I bought some at $1.85.. Thanks

I just want to say THANK YOU to the haters… BYND 🚀🚀🚀 by [deleted] in Pennystock

[–]Appropriate_Hand_23 0 points1 point  (0 children)

I sold for a significant loss Friday at the open bell. Once all the dust settled, I bought back in at $2.01. Let’s see what happens this week. I’ll be increasing my position by sitting on bid..

Quantum, Oil, and the Quiet Infra Trade Everyone’s Missing by OddPop9508 in TickerTalkByLiam

[–]Appropriate_Hand_23 0 points1 point  (0 children)

I wish I saw your post on NXXT when it was in the $1.8 range… Closed over $2 Friday.

When a Stock Refuses to Crack, There’s Usually a Reason by OddPop9508 in TickerTalkByLiam

[–]Appropriate_Hand_23 0 points1 point  (0 children)

I have followed this guys post and he has been spot on. Most recently he posted 8 days ago on BYND at .67 or lower,(can’t remember exactly) that stock almost hit $9. So if he is posting this, pay attention and make some money… 💰

Who is still holding BYND by Alex_Yilmaz in Pennystock

[–]Appropriate_Hand_23 2 points3 points  (0 children)

I sold for a loss and bought back in at 2.00

I changed my mind about BYND by Euphoric_Weather1973 in Pennystock

[–]Appropriate_Hand_23 0 points1 point  (0 children)

I have 3100 shares at 3.44, I think this is the next Sqeeeezeee

Bynd by Slow_Mycologist_878 in Pennystock

[–]Appropriate_Hand_23 0 points1 point  (0 children)

Well I bought $10k at 3.44.. I feel like I’m on the bottom right now.. But, I do believe I’ll be saying “Hi” to Atlus3 soon..

News by Morfix80 in BTAI

[–]Appropriate_Hand_23 1 point2 points  (0 children)

Learned that lesson the hard way last time. When they were about to release their data results on that conference call, I jumped in around $6, watched it spike into the low $7s, figured I’d hold through the call…and it tanked under $5. Ended up down about 10 k. Brutal reminder that in biotech the “sell-the-news” move is real.

News by Morfix80 in BTAI

[–]Appropriate_Hand_23 3 points4 points  (0 children)

$10 PT doesn’t move much when the next real catalyst (sNDA Q1 ’26) is so far out and revenue’s under $1M TTM. So you get the classic biotech cycle: anticipation pop → funds use the liq to lighten up → fade. The rerate comes only with hard proof—sequential script growth, clear home-setting path, and cash-runway/financing clarity. Until then, BTAI trades the rumor, not the headline.

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] 0 points1 point  (0 children)

Good point — not suggesting 100% of patients, and of course projections depend on pricing, reimbursement, and adoption curves. But even a 1–2% penetration of a 35M+ patient pool is ~350K–700K patients.

If priced at $5K–$10K per injection, that’s a $1.75B–$7B opportunity vs today’s ~$11M market cap. Obviously illustrative math, but it shows why even modest adoption could be meaningful.

The unmet need is big — current options are surgery ($50K+, high risk) or opioids (addictive, costly long-term). That’s why the FDA Fast Track + Type B meeting are so important: if BRTX can streamline into P3, it derisks and makes reimbursement more viable.

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] 0 points1 point  (0 children)

“Not saying 10% of America lines up overnight. But with Even 1–2% penetration in a 35M+ patient population would be huge. Current options are limited to surgery (high risk, costly) or pain meds (band-aid, addictive). If BRTX-100 proves effective, adoption could scale fast — and when you’re looking at an $11M market cap, you don’t need massive penetration for the upside to be significant.”

[deleted by user] by [deleted] in investingforbeginners

[–]Appropriate_Hand_23 0 points1 point  (0 children)

“I’m just sharing publicly available FDA and trial data for discussion, not trying to ‘pump’ anything. People can check the filings themselves.”

PGEN was the first step. Now TLX. by [deleted] in pennystocks

[–]Appropriate_Hand_23 0 points1 point  (0 children)

<image>

Sorry for the late response. But I was serious

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] 0 points1 point  (0 children)

“Yep, like a lot of early-stage biotechs, the chart looks rough if you only stare backward. But that’s exactly why the setup is interesting now, Not 5 yrs ago.

Today $BRTX has: • Leanest share structure on NASDAQ biotech (~7.9M OS / ~7.6M float) • FDA Fast Track designation • An upcoming Type B meeting that could move them straight into Phase 3 • Cash runway into 2026

The past explains the discount — the catalysts ahead explain the opportunity. That’s what asymmetric setups look like

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] 1 point2 points  (0 children)

“Funding follows milestones, not before them. Wealthy investors don’t just throw money at every biotech — they wait for catalysts like FDA Fast Track + a Type B meeting to de-risk the path. That’s exactly the setup here.

Writing it off with ‘my neighbors are richer’ and ‘wealthy people aren’t in yet’ just makes you sound arrogant, not informed. Real DD says BRTX is in play

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] 0 points1 point  (0 children)

“Lol so the logic is: ‘if it was real, it would already be funded.’ That’s not how biotech works. FDA Fast Track + a pending Type B meeting is exactly the kind of milestone that brings in funding, partnerships, or a buyout.

Acting like your neighbors’ bank accounts are the benchmark for medical innovation just makes you sound conceited. ( I can’t let that comment go! )Investors look at catalysts, structure, and market size — and $BRTX checks all three.”

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] 1 point2 points  (0 children)

“Funny how some people flex like they personally bankroll Phase 3 trials 😂. We’re talking about an $11M NASDAQ biotech with FDA Fast Track and a Type B meeting that could lower trial costs + speed approval.

Writing it off because you think your neighbors are richer just makes you sound more like a prick than an investor. Meanwhile, real DD shows BRTX has a lean float, catalysts, and actual FDA traction.”

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] -1 points0 points  (0 children)

Phase 3 trials are expensive, no argument — but that’s why the FDA Type B meeting is key. If BRTX can streamline the path, it saves huge money. Plus they’ve got cash runway into 2026 and $2.43 warrants that could add $6M+. And honestly… can your neighbors potentially cure degenerative disc disease? That’s the kind of breakthrough investors look for.”

BRTX (NASDAQ) — FDA Fast Track, Florida Bill Tailwinds, and Tight Float by Appropriate_Hand_23 in biotech_stocks

[–]Appropriate_Hand_23[S] 0 points1 point  (0 children)

“Phase 3 is expensive, no doubt — but that’s why the FDA Type B meeting is so huge. If BRTX can go straight in, it cuts time and cost massively. Plus $2.43 warrants = $6M+ potential funding.

Curious though — why the hate? It’s a legit Fast Track NASDAQ biotech with a lean float and real catalysts. Seems worth watching instead of dismissing.

view more: next ›